Abvion provides a protein‑level serological discovery service called AbDirect that isolates mature, high‑affinity human antibodies directly from biofluids, including archived biobank samples, using high‑resolution mass‑spectrometry proteomics. The platform delivers in‑vivo‑evolved antibody sequences that require minimal engineering, enabling biopharma and research partners to accelerate therapeutic antibody development with superior efficacy and tolerability.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional antibody discovery relies on in vitro selection or animal immunization, which often yields candidates that lack the natural affinity maturation and tolerability of human immune responses. Accessing mature, high‑affinity human antibodies from patient samples is technically challenging, limiting the speed and success rate of therapeutic development.
Solution
Abvion addresses this gap with its AbDirect platform, a protein‑level serological discovery technology that directly isolates antibodies from human biofluids, including archived biobank specimens. By leveraging high‑sensitivity mass‑spectrometry proteomics, the platform captures battle‑tested, in‑vivo‑evolved antibody sequences without the need for recombinant expression or animal immunization. The resulting antibodies are mature, human‑derived, and exhibit superior efficacy and tolerability profiles, providing ready‑to‑engineer blueprints for therapeutic programs. Abvion offers this capability as a collaborative service, enabling partners to accelerate the identification of clinically relevant antibodies for a range of disease areas.
Target Audience
Primary customers are biopharma companies seeking to enrich their antibody pipelines and academic or research institutions with biobanks that require advanced serological discovery capabilities.
Features
- Direct protein‑level capture of antibodies from complex biological samples using high‑resolution mass‑spectrometry
- Ability to mine archived biobank and serum specimens, expanding access to rare or historical immune responses
- Generation of mature, in‑vivo‑affinity‑matured antibody sequences that require minimal downstream engineering
- High sensitivity and precision that detect low‑abundance antibodies missed by conventional screening methods
- Integrated bioinformatic pipeline to annotate, rank, and select candidate antibodies based on functional and developability criteria